Exact Mass: 462.0998

farnesyl triphosphate

C15H29O10P3 (462.0974)

2-Ethoxy-3-[4-[2-[4-(trifluoromethylsulfonyloxy)phenyl]ethoxy]phenyl]propanoic acid

C20H21F3O7S (462.096)

Antibiotic DC 116

C25H18O9 (462.0951)

inoscavin A

C25H18O9 (462.0951)

emeguisin C

C24H24Cl2O5 (462.1001)

C25H18O9

C25H18O9 (462.0951)

C24H24Cl2O5

C24H24Cl2O5 (462.1001)

emeguisin C

C24H24O5Cl2 (462.1001)

di(propan-2-yl)-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)silane

C14H19F13Si (462.1048)

n-[(3-trimethoxysilyl)propyl]ethylenediamine triacetic acid trisodium salt

C14H25N2Na3O9Si (462.1022)

Eletriptan HBr

C22H27BrN2O2S (462.0977)

D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist Eletriptan hydrobromide (Eletriptan HBr) is a selective 5-HT1B and 5-HT1D receptor agonist with Ki of 0.92 nM and 3.14 nM, respectively.

Acid Orange 156

C21H19N4NaO5S (462.0974)

BMS-908662 free base

C24H19ClN4O4 (462.1095)

Rintodestrant

C26H19FO5S (462.0937)

C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2116 - Selective Estrogen Receptor Down Regulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist

[4-[(Z)-[3-(2-aminoethyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]-2-methoxyphenyl] 2,5-dimethylbenzenesulfonate

C21H22N2O6S2 (462.0919)

Aspartyl-adenosine-5-monophosphate

C14H19N6O10P (462.09)

7-(Methylthio)heptyl-glucosinolate

C15H28NO9S3- (462.0926)

8-chloro-2-(2-phenylethyl)chromone-6-O-glucoside

C23H23ClO8 (462.1081)

7-(3,4-Dihydroxyphenyl)-4-hydroxy-3-(4-hydroxy-3,5-dimethoxyphenyl)-2,8-dioxatricyclo[7.3.1.05,13]trideca-1(12),3,5(13),6,9-pentaen-11-one

C25H18O9 (462.0951)

3-L-aspartyl-AMP

C14H19N6O10P (462.09)

An L-aspartic acid derivative that is the ester obtained by formal condensation of the alpha-carboxy group of L-aspartic acid with the 3-hydroxy group of AMP.

4-methoxy-N-[2-[(4-nitrophenyl)methylthio]-4-oxo-3-quinazolinyl]benzamide

C23H18N4O5S (462.0998)

2-acetamido-2-deoxy-3-O-(6-O-sulfonato-beta-D-glucosyl)-beta-D-galactose

C14H24NO14S- (462.0917)

(2S)-2-[[2-amino-9-[(2R,4S,5R)-4-hydroxy-5-(phosphonooxymethyl)oxolan-2-yl]purin-6-yl]amino]butanedioic acid

C14H19N6O10P (462.09)

N6-Succino-2-amino-2'-deoxyadenylate

C14H19N6O10P (462.09)

MDM2-IN-1

C23H21Cl2FN2O3 (462.0913)

MDM2-IN-1 (Compound 30) is a synthetic MDM2-p53 interaction (MDM2) inhibitor and contains the trans (D-)configuration[1].

RLX-33

C24H19ClN4O4 (462.1095)

RLX-33 is a potent, selective and blood-brain barrier (BBB) penetrant relaxin family peptide 3 (RXFP3) antagonist, also blocks relaxin-3-induced ERK1/2 phosphorylation, with IC50 values of 2.36 μM for RXFP3, 7.82 and 13.86 μM for ERK1 and ERK2 phosphorylation, respectively. RLX-33 can block the stimulation of food intake induced by the RXFP3-selective agonist R3/I5 in rats. RLX-33 can be used for the research of metabolic syndrome[1].

4,12-bis(but-2-en-2-yl)-5,13-dichloro-14-hydroxy-6-methoxy-7,15-dimethyl-2,9-dioxatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one

C24H24Cl2O5 (462.1001)

2'-(3,4-dihydroxyphenyl)-6'-[2-(3,4-dihydroxyphenyl)ethenyl]-5-methyl-2'h-spiro[furan-2,3'-furo[3,2-c]pyran]-3,4'-dione

C25H18O9 (462.0951)

{8,11-dihydroxy-2-[2-methyl-3-(prop-1-en-1-yl)oxiran-2-yl]-4,7,12-trioxo-1-oxatetraphen-5-yl}acetic acid

C25H18O9 (462.0951)

3-[4,5-dihydroxy-2-(6-methyl-4-oxopyran-2-yl)phenyl]-6-[(1e)-2-(3,4-dihydroxyphenyl)ethenyl]-4-hydroxypyran-2-one

C25H18O9 (462.0951)

4,6-dichloro-9-hydroxy-3,3,17-trimethyl-2,12-dioxapentacyclo[9.8.3.1¹⁰,¹⁴.0¹,⁶.0⁸,²¹]tricosa-8(21),9,11(22),14,17-pentaene-7,20-dione

C24H24Cl2O5 (462.1001)

(6ar,9r,9as)-9-acetyl-5-bromo-3-[(1e,3e,5s)-3,5-dimethylhepta-1,3-dien-1-yl]-6a-methyl-1h,9h,9ah,9bh-furo[2,3-h]isochromene-6,8-dione

C23H27BrO5 (462.1042)

(2s,2's)-2'-(3,4-dihydroxyphenyl)-6'-[(1e)-2-(3,4-dihydroxyphenyl)ethenyl]-5-methyl-2'h-spiro[furan-2,3'-furo[3,2-c]pyran]-3,4'-dione

C25H18O9 (462.0951)

4,12-bis[(2e)-but-2-en-2-yl]-5,13-dichloro-14-hydroxy-6-methoxy-7,15-dimethyl-2,9-dioxatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one

C24H24Cl2O5 (462.1001)

{8,11-dihydroxy-2-[(2s,3s)-2-methyl-3-[(1z)-prop-1-en-1-yl]oxiran-2-yl]-4,7,12-trioxo-1-oxatetraphen-5-yl}acetic acid

C25H18O9 (462.0951)

(2r,2'r,3s,3'r,3'ar)-3'-hydroxy-5'-methyl-3,3'a-bis(methylsulfanyl)-3h,3'h-dispiro[1-benzofuran-2,6'-[1,2]oxazolo[2,3-a]pyrazine-2',1''-cyclohexan]-3''-ene-2'',4',7'-trione

C21H22N2O6S2 (462.0919)

(1s,4r,6r,14e,17e)-4,6-dichloro-9-hydroxy-3,3,17-trimethyl-2,12-dioxapentacyclo[9.8.3.1¹⁰,¹⁴.0¹,⁶.0⁸,²¹]tricosa-8(21),9,11(22),14,17-pentaene-7,20-dione

C24H24Cl2O5 (462.1001)

3-[4,5-dihydroxy-2-(6-methyl-4-oxopyran-2-yl)phenyl]-6-[2-(3,4-dihydroxyphenyl)ethenyl]-4-hydroxypyran-2-one

C25H18O9 (462.0951)